cobas ® SARS-CoV-2

Help prevent the silent spread of SARS-CoV-2

SARS-CoV-2 may be difficult for clinicians to identify on symptoms alone. Many patients may be asymptomatic and if left undiagnosed, it may result in health complications or community spread.

With more than 4.5 million deaths and over 218 million cases¹ of COVID-19 reported so far worldwide, effective tools are needed to deliver rapid results to identify symptomatic and asymptomatic individuals.

cobas^® SARS-CoV-2 is the first real-time polymerase chain reaction (PCR) test that provides targeted identification within 20 minutes for both asymptomatic and symptomatic persons, enabling informed decisions at the point of care.

cobas^® SARS-CoV-2:

Screen asymptomatic individuals in 20 minutes to help prevent the silent spread of SARS-CoV-2
Mobilize fast testing at your priority points of care for greater access for patients
Broad strain coverage of SARS-CoV-2 variants for further reassurance with care decisions

The cobas^® SARS-CoV-2 assay runs on the cobas^® Liat^® System. A growing menu of molecular POC assays, together with this innovative analyzer, and the connectivity of cobas^® infinity POC solution, forms the Roche total point-of-care PCR solution. Now, emergency rooms, primary care and other novel POC settings can reliably standardize and mobilize molecular testing, enhancing patient safety and satisfaction.

cobas^® SARS-CoV-2 Performance*

Symptomatic individuals

LOD: 1.2 x 10^-2 TCID ₅₀/mL

Positive Agreement^**

(95% CI: 89.0%-98.6%)

Negative Agreement^**

(95% CI: 92.6%-98.6%)

Asymptomatic individuals

LOD: 1.2 x 10^-2 TCID₅₀/mL

Positive Agreement^**

(95% CI: 84.5%-100%)

Negative Agreement^**

(95% CI: 96.2%-99.7%)

* cobas^® SARS-CoV-2 Nucleic acid test for use on the cobas^® Liat^® System, Package Insert V01, Pleasanton, CA; Roche Molecular Systems, Inc., 2021.
** Compared to FDA EUA SARS-CoV-2 RT-PCR assays; IFU data.
CI=confidence intervals. LOD=limit of detection. TCID=tissue culture infective dose.

Learn more about the expanding menu of assays

cobas^® SARS-CoV-2 & Influenza A/B Assay

Detect and differentiate SARS-CoV-2, influenza A and influenza B in 20 minutes from a single sample and in just one RT-PCR test for use on the cobas® Liat® System

cobas^® Influenza A/B & RSV Assay

Diagnose and differentiate influenza A/B & RSV for effective clinical management and infection control with the POC multiplex PCR test for use on the cobas® Liat® System.

cobas^® Strep A Assay

With lab-quality results in ~15 minutes, cobas® Strep A, for use on the cobas® liat system aids clinicians to make immediate, informed treatment decisions.

cobas^® Cdiff

Provide accurate, on-demand results in 20 minutes for the detection of toxigenic C. diff with the POC PCR test for use on the cobas® Liat® System

...

cobas^® Liat^® System

Rapidly test, triage, and treat your patients with the accuracy, simplicity, and security needed at the point of care.

Learn more

Total commitment deserves the total point-of-care PCR solution

Elevating care across your POC testing ecosystem

Learn more

Intended Use

CE-IVD

The cobas^® SARS-CoV-2 Nucleic acid test for use on the cobas^® Liat® System (cobas^® SARS-CoV-2) is an automated real-time RT-PCR assay intended for the rapid in vitro qualitative detection of SARS-CoV-2 in self-collected nasal swabs (collected in a healthcare setting with instruction by a healthcare provider) and healthcare provider-collected nasopharyngeal and nasal swabs from either individual suspected of respiratory viral infection consistent with COVID-19 by their healthcare provider or from individuals without symptoms or other reasons to suspect COVID-19.

cobas^® SARS-CoV-2 is intended for use in the detection of SARS-CoV-2 in clinical specimens. SARS-CoV-2 viral RNA is generally detectable in upper respiratory specimens during the acute phase of infection. Positive results are indicative of active infection but do not rule out co‑infection with other pathogens not detected by the test. Clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. The agent detected may not be the definite cause of disease.

Negative results do not preclude infection from SARS-CoV-2 and should not be used as the sole basis for diagnosis, treatment or other patient management decisions. Negative results must be combined with clinical observations, patient history, and/or epidemiological information.

cobas^® SARS-CoV-2 is intended for use by health professionals or trained operators who are proficient in using the cobas^® Liat^® System at the point of care (POC) or in a clinical laboratory setting.

US FDA EUA

The cobas^® SARS-CoV-2 Nucleic acid test for use on the cobas^® Liat^® System (cobas^® SARS-CoV-2) is an automated real-time RT-PCR assay intended for the rapid in vitro qualitative detection of nucleic acid from SARS-CoV-2 in self-collected anterior nasal (nasal) swabs (collected in a healthcare setting with instruction by a healthcare provider) and healthcare provider-collected nasopharyngeal, mid-turbinate and anterior nasal (nasal) swabs from either individuals suspected of COVID-19 by their healthcare provider or from any individual, including individuals without symptoms or other reasons to suspect COVID-19.

Results are for the identification of SARS-CoV-2 nucleic acids. SARS-CoV-2 RNA is generally detectable in respiratory specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA. Positive results do not rule out bacterial infection or co-infection with other viruses. Clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. The agent detected may not be the definite cause of disease.

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for diagnosis, treatment or other patient management decisions. Negative results must be combined with clinical observations, patient history, and/or epidemiological information.

cobas^® SARS-CoV-2 is intended for use by health professionals or trained operators who are proficient in using the cobas Liat System.

In the United States (US), testing with cobas^® SARS-CoV-2 is authorized for laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet requirements to perform moderate or high complexity tests. cobas^® SARS-CoV-2 is also authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

Laboratories within the U.S. and its territories are required to report all SARS-CoV-2 results to the appropriate public health authorities.

In the U.S., cobas^® SARS-CoV-2 is only for use under the Food and Drug Administration’s Emergency Use Authorization."

Registration status

CE-IVD, FDA Emergency Use Authorization (EUA)

The cobas^® Liat^® System is commercially available in select markets. This product is not registered as an in vitro diagnostic (IVD) in all countries; additional information may be available from your Roche sales representative.

Package inserts

Access package inserts through your country’s Roche Diagnostics Website.